KOSDAQBiotech & Pharma318160

Cell Bio Human Tech

₩5,040▼ 0.20%2026-11-18 close
Market Cap
₩47.3B
Turnover
₩31,667,980
Volume
6.3K
Shares out.
9.4M
PER
4.9×
PBR
0.7×
EPS
₩993
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Growth Is Clear; Margin Recovery Is the Test

Q3 2026 sales of KRW 22.3 billion were a company-record quarter, but operating profit of KRW 2.71 billion fell year on year, so recovery in consolidated profitability is the next test.

  1. 1

    Q3 2026 sales of KRW 22.3 billion rose 53.1% year on year and have grown for two straight quarters since the Q1 2026 low.

  2. 2

    Operating profit of KRW 2.71 billion fell 25.0% year on year in the same quarter, which the company attributed to cost and inventory system changes at some subsidiaries and inventory valuation effects.

  3. 3

    FY2025 sales reached KRW 51.1 billion (up 79.7%) and operating profit KRW 9.32 billion (up 130.8%), with the operating margin at 18.2%, the highest of the 2022–2025 period.

  4. 4

    On capacity, the Hwaseong No. 2 plant is designed to roughly double hydrocolloid output, while an earlier plan to buy a new factory was withdrawn.

  5. 5

    The debt ratio rose to 49.9% at end-2025 from 14.0% in 2024, and operating cash flow fell to KRW 1.49 billion in 2025 from KRW 9.27 billion in 2024.

02

Business structure

Cell Bio Human Tech started as a maker of functional fiber materials for mask pack sheets and has since widened into cosmetics OEM and ODM manufacturing and its own brand, pursuing a shift toward a full-scale cosmetics company.

Its core business is OEM and ODM manufacturing centered on hydrogel mask packs and sheets, and the company says it has commercialized 'Cell Series' and 'Semi Gel' materials using cellulose molecular control technology.

Based on a securities report published in February 2026, the cumulative sales mix for the first nine months of 2025 was 43.4% PT Cell products, 20.3% Semi Gel products, 14.7% cosmetics OEM, hydrocolloid and brand businesses, and 21.6% other.

Including hydrocolloid and hydrogel products, OEM and ODM-related sales were reported in early October 2026 to be about 34% of the total. Facilities comprise the Anyang headquarters and lab, the Hwaseong cosmetics and hydrocolloid plants, and a production unit in Da Nang, Vietnam.

Subsidiaries include Shinsedae (51% stake), acquired in 2025, Y&L Trading (67%) and Irum (100%). The company is an OEM partner to a large Chinese beauty client and works with several leading domestic brands, and reports from November 2025 said it has built collaboration with Olive Young and Amorepacific.

Its competitive positioning rests on supplying higher-performance raw materials to a mask pack materials market that had relied on low-cost Chinese nonwoven fabrics. The company obtained CGMP certification from the Ministry of Food and Drug Safety in 2026 and runs its own clean beauty brand, Lusom.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩14.5B₩3.6B24.9%
2025Q4₩14.3B₩1.2B8.5%
2026Q1₩12.7B₩1.5B11.4%
2026Q2₩19.4B₩3.5B18.0%
2026Q3₩22.3B₩2.7B12.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩27.5B₩3.5B₩2.9B12.8%9.0%43.0%
2023₩27.3B₩3.1B-₩1.9B11.5%−4.2%19.4%
2024₩28.4B₩4B₩4.4B14.2%9.4%14.0%
2025₩51.1B₩9.3B₩8.7B18.2%15.4%49.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales on a disclosed basis went from KRW 27.5 billion in 2022 to KRW 27.3 billion in 2023 (down 0.8%), then KRW 28.4 billion in 2024 (up 4.0%) and KRW 51.1 billion in 2025 (up 79.7%). After the 2023 low, sales rose in 2024 and 2025, and 2025 was the largest year of the 2022–2025 span.

Operating profit went from KRW 3.53 billion in 2022 to KRW 3.15 billion in 2023 (down 10.9%), then KRW 4.04 billion in 2024 (up 28.2%) and KRW 9.32 billion in 2025 (up 130.8%). The operating margin moved from 12.8% in 2022 to 11.5% in 2023, 14.2% in 2024 and 18.2% in 2025.

Net income attributable to controlling shareholders swung from KRW 2.89 billion in 2022 to a net loss of KRW 1.86 billion in 2023, returned to a profit of KRW 4.38 billion in 2024, and reached KRW 8.72 billion in 2025 (up 99.2%).

Net income including non-controlling interests, at KRW 8.7 billion in 2025, is a different measure and should not be read as the same figure. At end-2025, total equity was KRW 59 billion, of which KRW 56.7 billion belonged to controlling shareholders, and total liabilities were KRW 29.5 billion.

The debt ratio was 43.0% in 2022, 19.4% in 2023 and 14.0% in 2024 before rising to 49.9% in 2025, the year the company issued exchangeable bonds. Operating cash flow fell from KRW 9.27 billion in 2024 to KRW 1.49 billion in 2025, moving in the opposite direction to profit.

On a quarterly basis, sales were KRW 14.5 billion in Q3 2025, KRW 14.3 billion in Q4 2025 (down 2.0% quarter on quarter), KRW 12.7 billion in Q1 2026 (down 10.6%), KRW 19.4 billion in Q2 2026 (up 51.9%) and KRW 22.3 billion in Q3 2026 (up 14.9%).

Operating profit of KRW 3.49 billion in Q2 2026 (up 139.7% quarter on quarter) coincided with the company saying temporary Q1 factors were resolved in Q2. Q3 2026 operating profit of KRW 2.71 billion fell 22.4% quarter on quarter and 25.0% year on year, moving against sales.

Net income attributable to controlling shareholders over the last four quarters (Q4 2025 to Q3 2026) totaled KRW 8.79 billion.

05

Industry analysis

Demand for mask pack materials has depended heavily on China-bound volumes. A November 2025 report said Chinese mask pack demand had been weak for a long period since 2018 and that the reopening effect was slow. The company's sales rebounded from 2024, when Chinese mask sheet demand entered a recovery phase.

Recent coverage says the company's technology and business potential are being re-evaluated amid the K-beauty sector's momentum. In materials, its positioning rests on offering higher-performance inputs to a market that had relied on low-cost Chinese nonwoven fabrics.

The company says its cellulose molecular control technology raised absorbency up to 14 to 15 times that of conventional nonwovens, a claim made by the company itself. In cosmetics OEM and ODM work, orders are placed per purchase order under basic contracts, so long-term supply contracts are few.

Under that model, spare capacity translates directly into additional sales, which makes the pace of facility expansion a binding constraint on growth. Utilization was reported at 112% for the subsidiary and 102% at the Mado plant for the first nine months of 2025.

How far production capacity can keep pace with demand will likely shape the company's position within the sector.

06

Outlook

The company plans to run the Hwaseong No. 2 plant as a dedicated hydrocolloid base. According to a report in early October 2026, the target was to finish construction within October and start trial operations in November, with trial operations to begin by December 2026 even if the schedule slips.

Once running, hydrocolloid capacity is expected to rise by roughly 100%, and the company estimates annual capacity will expand from about KRW 4 billion to about KRW 8.2 billion.

The company also estimates theoretical annual sales capacity for its materials business rose from about KRW 55 billion before the expansion to KRW 60 to 65 billion.

Separately, a contract to buy a new factory signed in December 2025 was cancelled in February 2026 after the seller said the property was subject to a restriction on disposal, and the company reportedly is in talks over other properties.

The company said growth in its core business continued in Q3 2026 and that it plans to restore consolidated profitability through better management systems.

A securities firm outlook reported in September 2026 projected 2026 standalone sales of KRW 66.8 billion (up 31%) and operating profit of KRW 10 billion (up 192%), which are forecasts rather than reported results. The company said it is reviewing shareholder return measures including share cancellation and dividends. The next check is the operating margin in the Q4 2026 results and in the 2026 annual report.

07

Valuation

PER
4.9×
PBR
0.7×
ROE
15.5%
EPS
₩993
BPS
₩6,786
Dividend per share
₩0

The price-to-book ratio sits in a range that is at a discount to net asset value, so the share price is low relative to book value attributable to controlling shareholders. Measured against the KRW 56.7 billion of controlling-shareholder equity at end-2025, the share price is below net asset value.

Multi-year results show a clear recovery, from a net loss in 2023 to a profit in 2024 and KRW 8.72 billion in controlling-shareholder net income in 2025. Net income attributable to controlling shareholders over the last four quarters totaled KRW 8.79 billion, close to the FY2025 level.

Quarterly earnings are volatile, however, with the figure falling 40.3% from KRW 2.93 billion in Q2 2026 to KRW 1.75 billion in Q3 2026. Earnings multiples depend heavily on which quarters are used, so one quarter is hard to read in isolation.

Whether shareholder return measures such as share cancellation and dividends are actually carried out is the next point to check. How those measures take shape will determine how any dividend expectations compare with peers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Continued top-line growth

Q3 2026 sales of KRW 22.3 billion rose 53.1% year on year, which the company announced as its largest quarter since its founding. Sales have increased for two consecutive quarters after KRW 19.4 billion in Q2 2026. The company says both its core materials business and its cosmetics OEM and ODM share are growing.

Improving profit structure

The operating margin rose from 12.8% in 2022 to 18.2% in 2025. Operating profit in 2025 reached KRW 9.32 billion, up 130.8%, and net income attributable to controlling shareholders recovered to KRW 8.72 billion from the 2023 loss.

One brokerage attributed the margin gains to product mix shifts and the effects of production moving to Vietnam.

Capacity expansion may ease constraints

The company says hydrocolloid capacity will roughly double once the Hwaseong No. 2 plant runs. Its own estimate puts theoretical annual sales capacity for materials at KRW 60 to 65 billion. Utilization had exceeded 100% in 2025, so added capacity would widen room to take orders.

09

Bear factors

Profit moved against sales in Q3

Q3 2026 operating profit of KRW 2.71 billion fell 22.4% quarter on quarter and 25.0% year on year, even as sales increased.

The company attributed the decline to cost and inventory management changes at some subsidiaries and related inventory valuation effects, and said it plans to restore profitability through improved systems.

Uncertain capacity and expansion timing

Utilization for the first nine months of 2025 was reported at 112% for the subsidiary and 102% at the Mado plant. The December 2025 agreement to buy a new factory was cancelled in February 2026.

Trial operations at the No. 2 plant could slip past the November target, leaving open whether capacity can keep up with demand.

Earnings volatility and financial strain

Net income attributable to controlling shareholders fell 50.3% year on year to KRW 1.75 billion in Q3 2026. The debt ratio rose to 49.9% at end-2025, a year in which exchangeable bonds were issued.

Operating cash flow dropped to KRW 1.49 billion in 2025 from KRW 9.27 billion in 2024, so whether profit gains convert into cash remains to be seen.

10

Risk factors

Demand structure and customer concentration

Cosmetics OEM and ODM orders are placed per purchase order under basic contracts, leaving few long-term supply agreements. Order adjustments by a major Chinese beauty client contributed to earlier weak results, so swings in that client or China-bound demand could affect sales directly.

Cost and inventory management systems

The Q3 2026 profit decline was explained by inventory valuation effects from aligning cost and inventory accounting at some subsidiaries with the parent. Management improvements across subsidiaries are under way, and their effect on results may take time to appear.

Funding and expansion plans

The company raised funds through exchangeable bonds in 2025, and cancellation of the new factory agreement changed its capacity plans. With the debt ratio rising and operating cash flow falling, pursuing further capital spending and shareholder returns at the same time could increase financial pressure.

11

What to watch next

  1. December 2026

    Whether trial operations begin at the Hwaseong No. 2 plant, showing if the hydrocolloid capacity expansion is going live.

  2. After December 2026 (timing not set)

    Whether shareholder return measures such as share cancellation and dividends are formally disclosed, and their scale.

  3. Mid-March 2027

    Q4 2026 preliminary results and the 2026 annual report, where the annual operating margin, debt ratio and operating cash flow are the key items. The FY2025 results were released on March 18, 2026.

  4. Mid-May 2027

    Q1 2027 results, which will show how quickly cost and inventory adjustments recover and whether capacity expansion shows up in sales. Q1 2026 results were released on May 14, 2026.

12

Overall view

Cell Bio Human Tech has grown its sales scale by widening its business from mask pack materials into cosmetics OEM and ODM manufacturing. Annual sales rose from KRW 27.5 billion in 2022 to KRW 51.1 billion in 2025, and the operating margin climbed from 12.8% to 18.2%.

Net income attributable to controlling shareholders recovered to KRW 8.72 billion in 2025 from a 2023 net loss.

Q3 2026 sales of KRW 22.3 billion were a company-record quarter, but operating profit fell 25.0% year on year to KRW 2.71 billion, which the company linked to cost and inventory system changes at some subsidiaries.

Bullish factors are top-line growth, expanded capacity from new facilities and the recent profit recovery trend. Bearish factors are the Q3 margin reversal, uncertainty over spare capacity and expansion timing, and a rising debt ratio alongside lower operating cash flow.

Next checkpoints are whether trial operations start at the Hwaseong No. 2 plant in December 2026, the annual operating margin and cash flow in the 2026 annual report, and whether cost adjustments show up in Q1 2027 results. This report is provided for information only and does not contain an investment opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. koreasprint.com
  2. kdpress.co.kr
  3. kcenews.kr
  4. etoday.co.kr
  5. specialtimes.co.kr
  6. newswire.co.kr
  7. welaunch.kr
  8. m.thebell.co.kr
  9. ibtomato.com
  10. leadeconomy.co.kr
  11. comp.fnguide.com
  12. investing.com
  13. kbthink.com
  14. ket.kr
  15. valueline.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis